AndhraNews.net
Home » Features » Education » Tel Aviv University

Tel Aviv University


Tel Aviv University in News

The University of Tel Aviv and its French Friends Meet at Paris' Hôtel de Ville to Reward Initiatives in Favor of Cooperation Between France and Israel
The University of Tel Aviv and its French Friends Meet at Paris' Hôtel de Ville to Reward Initiatives in Favor of Cooperation Between France and Israel

DEBATE: The Nuclear Deal With Iran Won't Make the World a Safer Place
NEW YORK, NY--(Marketwired - November 02, 2015) - Intelligence Squared hosts this major debate November 2nd at the Emmanuel Centre in London

Kalytera Appoints Stuart Silverman, MD to Scientific Advisory Board; Dr. Silverman Brings 40 Years' Expertise in Osteoporosis and Bone Healing
Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid ("CBD") and synthetic CBD medicines that address the unmet needs of large patient populations, today announced that a leading international expert in osteoporosis and chronic pain, Stuart Silverman, MD, FACP, FACR, has joined its Scientific Advisory Board.

Kalytera Therapeutics and Ramot at Tel Aviv University to Study Bone Healing Properties of Kalytera Drug Candidates; Companies to Pioneer Synthetic CBD Pharma Research
Kalytera Therapeutics, Inc

Stanford, MIT and Harvard top the inaugural Reuters Top 100 ranking of the most innovative universities
NEW YORK, SEPTEMBER 16, 2015 - Stanford University, the Massachusetts Institute of Technology and Harvard University top the inaugural Reuters Top 100 ranking of the world's most innovative universities. The Reuters Top 100 ranking aims to identify which institutions contribute the most to science and technology, and have the greatest impact on the global economy

oti Appoints Shlomi Cohen as Chief Executive Officer
The board of directors of On Track Innovations Ltd. (oti) (NASDAQ: OTIV), a global provider of near field communication (NFC) and cashless payment solutions, has appointed Shlomi Cohen as CEO, succeeding Ofer Tziperman.

BrainStorm Cell Therapeutics Inc.'s CEO Tony Fiorino Interviewed by The Life Sciences Report
An Israeli biotech is hard at work on a new treatment for neurodegenerative disease that holds promise in a variety of devastating diseases and enjoys fast-track and orphan drug status in its lead indication, amyotrophic lateral sclerosis (ALS). In this interview Dr. Tony Fiorino, the U.S.-based CEO of BrainStorm Cell Therapeutics Inc

LYCOS Advertising Appoints New GM
Business Wire IndiaLYCOS (NSE:LYCOS | BSE:532368 ), one of the most widely known Internet brands in the world and one of the first search engines on the web, today announced the appointment of Mrs. Gali Arnon as the new GM of its Advertising Division – LYCOS Advertising.   Mrs. Gali Arnon is the new GM of Ybrant Digital, LYCOS Advertising Division. Mrs

BrainStorm Hosting Conference Call to Update Shareholders on Major Developments
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, June 10, 2014 at 8:45 a.m. Daylight Saving Time (DST), 15:45 Israel Daylight Time (IDT). Mr

BrainStorm Completes Uplisting to the NASDAQ Capital Market
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market, and will commence trading on the NASDAQ Capital Market when trading begins on September 30, 2014.

BrainStorm Provides Update on NASDAQ Uplisting Process
Brainstorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that on September 15, 2014, it plans to effect a 1 for 15 reverse split of its issued and outstanding common stock as part of its intended plan to pursue a stock listing on the NASDAQ Capital Market.

BrainStorm Announces Publication of Preclinical Multidose Study of NurOwn
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today publication of an important preclinical study in the journal Clinical and Translational Medicine

Boston Therapeutics Appoints Benjamin Rivnay, Ph.D. to Chief Scientist
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Benjamin Rivnay, Ph.D. to serve as its Chief Scientist, a newly created position. In this role, Dr. Rivnay will be responsible for the development of the Company's science and technology

BrainStorm and Octane Successfully Construct a Bioreactor Prototype for Industrial-Scale Manufacturing or NurOwn Stem Cells
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc

BrainStorm Cell Therapeutics Raises $10.5 Million in Private Placement Financing
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System therapeutics, today announced that it has entered into definitive agreements with a group of investors, including several healthcare-focused funds, in connection with a private placement of common stock and warrants to purchase common stock

BrainStorm Expands Pipeline With Initiation of Pre-Clinical Study in Autism
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has initiated a study in a mouse model of autism at the Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, under the direction of Professor Daniel Offen

BrainStorm Cell Therapeutics Appoints Tony Fiorino, MD, PhD as Chief Executive Officer
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has appointed Tony Fiorino, MD, PhD as its new Chief Executive Officer (CEO).

First Patient Enrolled in BrainStorm's Phase II ALS Trial at Massachusetts General Hospital
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient was enrolled in its Phase II ALS trial at Massachusetts General Hospital (MGH) in Boston.

Positive Interim Phase IIa ALS Data With BrainStorm's NurOwn Presented at Joint Congress of European Neurology
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced that interim results from the Company's Phase IIa ALS trial conducted at Hadassah Medical Center in Jerusalem, Israel were presented yesterday at the Joint Congress of European Neurology by Principal Investigator Professor Dimitrios Karussis

BrainStorm Announces Redemption of Outstanding Warrants for Cash
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) announced today that it has entered into agreements with holders of warrants originally issued in the Company's August 16, 2013 public offering, to repurchase outstanding warrants to purchase an aggregate of approximately five (5) million shares of Company Common Stock, $0

BrainStorm to Present Phase IIa ALS Clinical Trial Data at the Joint Congress of European Neurology
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will be presenting initial results from its Phase IIa ALS trial at the Joint Congress of European Neurology in Istanbul, Turkey, May 31-June 3

BrainStorm Cell Therapeutics Presenting at Multiple Upcoming Conferences
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it is presenting at the following scientific and industry conferences this month.

FDA Approves Commencement of BrainStorm's Phase II ALS Clinical Trial in U.S.
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the US Food and Drug Administration (FDA) has approved commencement of its Phase II clinical trial with NurOwn™ in patients with Amyotrophic Lateral Sclerosis (ALS)

BrainStorm Announces Exchange of Outstanding Warrants
BrainStorm Cell Therapeutics (OTCQB: BCLI) announced today that it has entered into agreements with holders of warrants originally issued in the Company's August 16, 2013 public offering, to exchange outstanding warrants to purchase an aggregate of 11,662,059 shares of Company Common Stock, $0.00005 par value, and issue to the holders an aggregate of 5,831,031 shares of unregistered Common Stock

Orgenesis Appoints Joseph Tenne as Chief Financial Officer
Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, has appointed Joseph Tenne as chief financial officer.

BrainStorm Granted Additional US Patent for Its Autologous Stem Cell Technology
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office has granted the company an additional patent for its autologous stem cell technology. The patent (No

BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS), pending FDA and Institutional Review Board approvals

BrainStorm Granted Key US Patent for Its Autologous Stem Cell Technology
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office has granted the company a key patent for its autologous stem cell technology. The patent (No

BrainStorm Submits Favorable Interim Safety Report for Second Group of Patients in Its Phase IIa Dose-Escalating Trial of NurOwn(TM) in ALS
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has submitted a favorable safety report to the hospital Helsinki Committee (IRB) for the second group of patients in its ongoing Phase IIa ALS clinical trial at the Hadassah Medical Center in Jerusalem, Israel

Rosetta Genomics Issues Letter to Shareholders
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the posting of the following Letter to Shareholders to the Investors section of the Company's website at www.rosettagenomics.com.

International Conference in Chicago Examines Role of Research Universities in Addressing Urban Challenges

Rosetta Genomics Announces Sponsored Research Agreement With Ramot at Tel Aviv University
Rosetta Genomics Ltd

Distinguished Economists Propose to Return Private Capital to Housing Finance, in the Latest Milken Institute Review
Ellen Seidman (Urban Institute), Phillip Swagel (Milken Institute), Sarah Rosen Wartell (Urban Institute) and Mark Zandi (Moody's Analytics) offer a sweeping plan for rebooting America's housing finance system in the new issue of The Milken Institute Review.

Infinity AR Announces Augmented Reality Authority, Ori Inbar as Director
Infinity Augmented Reality, Inc. ("Infinity Augmented Reality" or "Infinity AR") (OTCQB: ALSO), the first augmented reality software platform to connect universally with digital eyewear, smartphones, tables, smart TVs and connected cars, is pleased to announce the addition of Ori Inbar as a director of the Company.

Rosetta Genomics and Ramot at Tel Aviv University Awarded Grant From Israeli Office of the Chief Scientist to Support Development of microRNA Oncology Therapeutics
Rosetta Genomics Ltd

BrainStorm's NurOwn Cell Therapy Receives Orphan Drug Designation in the European Union for ALS

The SpendSmart Payments Company Appoints Yaniv Schahar as Chief Technology Officer
The SpendSmart Payments Company (OTCQB: SSPC) -- a provider of payment solutions that support smart spending habits -- announced today the appointment of Yaniv Schahar to the Company's newly created position of Chief Technology Officer.

BrainStorm Signs Memorandum of Understanding With PRC Clinical for US Clinical Trial Management
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a Memorandum of Understanding (MOU) with PRC Clinical™, a Contract Research Organization (CRO) based in the San Francisco Bay Area, in anticipation of its planned Phase II multi-center ALS clinical trial in the United States.

Nuvilex, Inc.'s Medical Marijuana Subsidiary Will Be Part of Marijuana Research Boom
Nuvilex, Inc.'s (OTCQB: NVLX) subsidiary, Medical Marijuana Sciences, Inc., has already declared its focus will be on pancreatic cancer and cancers of the brain, and that research will put the company right in the middle of what is turning into a real explosion in the industry

Net Optics Presents New Network Security Approach to Combating Cyber Attacks at Today's International Cyber Security Conference
Net Optics, the leading provider of Total Application and Network Visibility solutions, announced that its CEO and President, Bob Shaw, will introduce Security-Centric SDN, its next-generation approach to network security monitoring at today's Yuval Ne'eman Workshop's Annual International Conference on Cyber Security at Tel Aviv University in Israel.

BrainStorm Treats 8th Patient in Phase IIa Trial; Completes Enrollment of Final 4 Patients
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has successfully treated the eighth patient in its ongoing Phase IIa ALS clinical trial at the Hadassah Medical Center in Jerusalem, Israel, thus completing treatment of the second of three cohorts

BrainStorm Receives 1.2 Million NIS Grant From Israel's Office of the Chief Scientist
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company has received the third installment of the 2013 grant from Israel's Office of the Chief Scientist (OCS) in the amount of approximately $335,000 (~1.2M NIS). The yearly grant for 2013, in the amount of $729,000 (~2

BrainStorm Announces CEO Interview With The Wall Street Analyst
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that The Wall Street Analyst conducted an audio interview yesterday with the Company's Chief Executive Officer Alon Natanson. The interview can be heard on The Wall Street Analyst website at the following link: http://thewallstreetanalysts

BrainStorm Provides Update on Clinical Trial and Scientific Conference Activities
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today provided an update on the company's current and upcoming clinical trial and scientific conference activities.

Bessemer Venture Partners Appoints Two New Vice Presidents
Bessemer Venture Partners (BVP), a $4 billion venture capital firm backing great entrepreneurs leading transformative startups and other high-growth companies, today announced Aviad Ariel's and Sunil Nagaraj's promotion to vice president

BrainStorm to Present at Several Scientific and Investment Conferences
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the company will be presenting at several upcoming scientific and investment conferences.

BrainStorm Partners With Dana-Farber for NurOwn(TM) Production in Phase II ALS Clinical Trial
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dana-Farber Cancer Institute ("Dana-Farber") has entered into an agreement to provide cGMP-compliant clean room facilities for production of BrainStorm's NurOwn™ stem cell candidate during its upcoming Phase II ALS trial in the USA

Results of NurOwn(TM) Clinical Trial Suggest Efficacy in ALS Patients
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today reported some of the final results from a clinical study evaluating the company's NurOwn™ technology in 12 ALS patients

The Valence Group Appoints Former ICL CEO Akiva Mozes to its Senior Executive Panel
The Valence Group, a specialist M&A investment bank offering advisory services to companies and investors in the chemicals, materials and related sectors, has announced the appointment of Akiva Mozes, former President and CEO of diversified chemical manufacturer Israel Chemicals Ltd. (ICL), to its Senior Executive Panel (SEP).

What you know matters more than who you know for professional success
When intelligence and socio-economic background (SEB) are pitted directly against one another, intelligence is a more accurate predictor of future career advancement, a new study has revealed.

Vaultive Announces Appointment of Leading Cloud Security Industry Experts to Advisory Board
Vaultive, a provider of cloud data encryption solutions designed to maintain the control, security and compliance of data processed by cloud-based services, today announced the formation of its Advisory Board, which includes notable cloud computing industry luminaries Dave Cullinane, CEO of SecurityStarfish, Jim Reavis, co-founder and executive director of the Cloud Security Alliance, and Dr

AtHoc Appoints Daniel Moskowitz VP of Finance and Administration
AtHoc, Inc., the pioneer and leader in network-centric emergency mass notification systems, today announced the appointment of Daniel Moskowitz as its new vice president of finance and administration. Daniel brings extensive experience in finance and operations that spans private, VC-backed companies as well as large public entities

Invisible Threats Key Theme of Net Optics' CEO Address at Today's International Cybersecurity Conference; Israel's Defense Minister, Eugene Kaspersky, Also Speaking
Net Optics, the industry's leading provider of intelligent access and monitoring solutions, today announced that its CEO and President, Bob Shaw, will address leading cybersecurity experts and defense officials from around the world at the Yuval Ne'eman Workshop's Annual International Conference on Cybersecurity at Tel Aviv University in Israel

Orgenesis Inc. Announces Appointment of Senior Leadership
Orgenesis Inc. (OTCBB: ORGS) ("Orgenesis" or the "Company"), a development stage company with a novel therapeutic technology dedicated to convert a patient's own liver cells into functional insulin-producing cells as a treatment for diabetes, is pleased to announce its executive leadership team with the appointments of Chief Executive Officer Jacob BenArie MBA, B.Sc

CA Technologies Reports First Quarter Fiscal Year 2013 Results
Revenue $1.145 Billion, Up 1 Percent in Constant Currency and Down 2 Percent as Reported GAAP EPS $0.51, Up 11 Percent in Constant Currency and 13 Percent as Reported Non-GAAP EPS $0.63, Up 16 Percent in Constant Currency and 15 Percent as Reported Cash Flow from Continuing Operations $183 Million, Up 10 Percent in Constant Currency and 28 Percent as Reported IP Transaction Adds $0

Naked mole rat may hold key to longer and healthier life for humans
A collaborative of researchers in Israel and the United States is working to uncover the secret to the n*ked mole rats' long - and active - lifespan.

Cosmic web of first stars when universe was in its infancy unveiled
Scientists have discovered a new way to detect the first stars when the universe was only 200 million years old and still emerging from its dark ages.

New data challenges Standard Model of particle physics
New data from BaBar, a particle accelerator at the U.S. Department of Energy's (DOE's) SLAC National Accelerator Laboratory, built by ten countries including the U.K., may suggest possible flaws in the Standard Model of particle physics, the reigning description of how the universe works on sub-atomic scales.

Computer therapy may help reduce anxiety disorder in kids
Researchers are pursuing a new method to address childhood anxiety over concerns that one in eight children suffer from an anxiety disorder in America.

Durable plastics that may replace metals may help reduce pollution
Scientists have been working to produce a biodegradable alternative to plastics to reduce pollution.

Smart phones users more willing to reveal private issues in public spaces
With endless applications, high-speed wireless Internet access, and free messaging services, smart phones have revolutionized the way we communicate, but at the cost of our privacy.

Dead Sea almost dried up entirely 120,000 years ago
During the last interglacial period, approximately 120,000 years ago, Dead Sea came close to drying up entirely, researchers under a drilling project have found.

'Dessert with breakfast diet' cuts cravings and helps prevent weight regain
Adding a cookie or cake to their daily breakfast diet may help dieters keep the pounds off.

Viruses target gut microbes and affect human health
Scientists have analyzed a bacterial immune system and revealed a common set of viruses that attack good bacteria in the human gut.

Air pollution ups risk of repeated heart attacks by 40pc
High pollution increases the risk of repeated heart attacks in cardiac patients by over 40 percent, a Tel Aviv University researcher has claimed.

Common acne medication can double risk of eye infections
Millions of teenagers who suffer from acne take popular prescription medications such as Accutane or Roaccutane to deal with the embarrassing skin blemishes.

Soon, therapy to freeze Parkinson's in its tracks
Researchers are developing a preventive therapy to halt symptoms in Parkinson's patients.

Soon, wonder jab that will kill 90pc of cancers
A vaccine that kills 90 per cent of cancers using the body's natural defence mechanisms could be widely available within six years, scientists say.

High MP3 volume puts teens at risk for early hearing loss
One in four teens is in danger of early hearing loss as a direct result of using MP3 players at high volume, researchers say.

Hypersensitive kids may develop Obsessive Compulsive Disorder
Hypersensitivity in childhood and religiously following childhood rituals, like regular schedules for meal, bath, and bed times, could predict development of Obsessive Compulsive Disorder (OCD) in the long run, a new study has revealed.

Soon, effective liquid solution to make hospitals safer and bacteria free
Scientists have developed an efficient and cost-effective liquid solution that can help fight antibiotic-resistant bacteria and keep more patients safe from life-threatening infections in hospitals.

Why couch potatoes pile on the pounds
A new study led by an Indian origin researcher had found that leading life as a couch potato, stretched out in front of the TV for hours can actually be "active inactivity" and cause an individual to pack on pounds.

Lighting 'sprites' in outer space may signal alien life
Colourful bursts of sprites, which are one of the most indefinable phenomena occurring in earth's atmosphere, may also flash in outer space, signalling the existence of alien life, a new study has revealed.

Bacteria swarms could inspire new generation of smart robots
Washington, Nov 18 (ANI): Tel Aviv University researchers have developed a computational model that explains how bacteria move in a swarm, which can be applied to man-made technologies, including computers, artificial intelligence, and robotics

'Silent killer' carbon monoxide help urbanites cope with noise pollution
Carbon monoxide (CO) - a tasteless, colourless and odourless gas - found in the exhaust of vehicles and generators has been dubbed the "silent killer" because excessive inhalation is lethal, poisoning the nervous system and heart.

Soon, computer software that gets rid of real-life 'parking wars'
Israel researchers have come up with a computer stimulator, 'Parkagent' that will aid in overcoming real-life parking challenges and offer a more proficient way to park.

'Modern' blade production started much earlier than previously thought
A new discovery by researchers at Tel Aviv University has pushed back the production of sophisticated blade hundreds of thousands of years earlier than originally thought.

Single dose of cortison may help prevent traumatic stress
A quick injection can prevent post-traumatic stress disorder in 60 percent of those who experience trauma, researchers say.

Comment on this story

Share